Cargando…

Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)

Background. Increasing antimicrobial resistance among pathogens causing complicated intra-abdominal infections (cIAIs) supports the development of new antimicrobials. Ceftolozane/tazobactam, a novel antimicrobial therapy, is active against multidrug-resistant Pseudomonas aeruginosa and most extended...

Descripción completa

Detalles Bibliográficos
Autores principales: Solomkin, Joseph, Hershberger, Ellie, Miller, Benjamin, Popejoy, Myra, Friedland, Ian, Steenbergen, Judith, Yoon, Minjung, Collins, Sylva, Yuan, Guojun, Barie, Philip S., Eckmann, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412191/
https://www.ncbi.nlm.nih.gov/pubmed/25670823
http://dx.doi.org/10.1093/cid/civ097
_version_ 1782368621022937088
author Solomkin, Joseph
Hershberger, Ellie
Miller, Benjamin
Popejoy, Myra
Friedland, Ian
Steenbergen, Judith
Yoon, Minjung
Collins, Sylva
Yuan, Guojun
Barie, Philip S.
Eckmann, Christian
author_facet Solomkin, Joseph
Hershberger, Ellie
Miller, Benjamin
Popejoy, Myra
Friedland, Ian
Steenbergen, Judith
Yoon, Minjung
Collins, Sylva
Yuan, Guojun
Barie, Philip S.
Eckmann, Christian
author_sort Solomkin, Joseph
collection PubMed
description Background. Increasing antimicrobial resistance among pathogens causing complicated intra-abdominal infections (cIAIs) supports the development of new antimicrobials. Ceftolozane/tazobactam, a novel antimicrobial therapy, is active against multidrug-resistant Pseudomonas aeruginosa and most extended-spectrum β-lactamase (ESBL)–producing Enterobacteriaceae. Methods. ASPECT-cIAI (Assessment of the Safety Profile and Efficacy of Ceftolozane/Tazobactam in Complicated Intra-abdominal Infections) was a prospective, randomized, double-blind trial. Hospitalized patients with cIAI received either ceftolozane/tazobactam (1.5 g) plus metronidazole (500 mg) every 8 hours or meropenem (1 g) every 8 hours intravenously for 4–14 days. The prospectively defined objectives were to demonstrate statistical noninferiority in clinical cure rates at the test-of-cure visit (24–32 days from start of therapy) in the microbiological intent-to-treat (primary) and microbiologically evaluable (secondary) populations using a noninferiority margin of 10%. Microbiological outcomes and safety were also evaluated. Results. Ceftolozane/tazobactam plus metronidazole was noninferior to meropenem in the primary (83.0% [323/389] vs 87.3% [364/417]; weighted difference, −4.2%; 95% confidence interval [CI], −8.91 to .54) and secondary (94.2% [259/275] vs 94.7% [304/321]; weighted difference, −1.0%; 95% CI, −4.52 to 2.59) endpoints, meeting the prespecified noninferiority margin. In patients with ESBL-producing Enterobacteriaceae, clinical cure rates were 95.8% (23/24) and 88.5% (23/26) in the ceftolozane/tazobactam plus metronidazole and meropenem groups, respectively, and 100% (13/13) and 72.7% (8/11) in patients with CTX-M-14/15 ESBLs. The frequency of adverse events (AEs) was similar in both treatment groups (44.0% vs 42.7%); the most common AEs in either group were nausea and diarrhea. Conclusions. Treatment with ceftolozane/tazobactam plus metronidazole was noninferior to meropenem in adult patients with cIAI, including infections caused by multidrug-resistant pathogens. Clinical Trials Registration. NCT01445665 and NCT01445678.
format Online
Article
Text
id pubmed-4412191
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-44121912015-04-29 Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI) Solomkin, Joseph Hershberger, Ellie Miller, Benjamin Popejoy, Myra Friedland, Ian Steenbergen, Judith Yoon, Minjung Collins, Sylva Yuan, Guojun Barie, Philip S. Eckmann, Christian Clin Infect Dis Articles and Commentaries Background. Increasing antimicrobial resistance among pathogens causing complicated intra-abdominal infections (cIAIs) supports the development of new antimicrobials. Ceftolozane/tazobactam, a novel antimicrobial therapy, is active against multidrug-resistant Pseudomonas aeruginosa and most extended-spectrum β-lactamase (ESBL)–producing Enterobacteriaceae. Methods. ASPECT-cIAI (Assessment of the Safety Profile and Efficacy of Ceftolozane/Tazobactam in Complicated Intra-abdominal Infections) was a prospective, randomized, double-blind trial. Hospitalized patients with cIAI received either ceftolozane/tazobactam (1.5 g) plus metronidazole (500 mg) every 8 hours or meropenem (1 g) every 8 hours intravenously for 4–14 days. The prospectively defined objectives were to demonstrate statistical noninferiority in clinical cure rates at the test-of-cure visit (24–32 days from start of therapy) in the microbiological intent-to-treat (primary) and microbiologically evaluable (secondary) populations using a noninferiority margin of 10%. Microbiological outcomes and safety were also evaluated. Results. Ceftolozane/tazobactam plus metronidazole was noninferior to meropenem in the primary (83.0% [323/389] vs 87.3% [364/417]; weighted difference, −4.2%; 95% confidence interval [CI], −8.91 to .54) and secondary (94.2% [259/275] vs 94.7% [304/321]; weighted difference, −1.0%; 95% CI, −4.52 to 2.59) endpoints, meeting the prespecified noninferiority margin. In patients with ESBL-producing Enterobacteriaceae, clinical cure rates were 95.8% (23/24) and 88.5% (23/26) in the ceftolozane/tazobactam plus metronidazole and meropenem groups, respectively, and 100% (13/13) and 72.7% (8/11) in patients with CTX-M-14/15 ESBLs. The frequency of adverse events (AEs) was similar in both treatment groups (44.0% vs 42.7%); the most common AEs in either group were nausea and diarrhea. Conclusions. Treatment with ceftolozane/tazobactam plus metronidazole was noninferior to meropenem in adult patients with cIAI, including infections caused by multidrug-resistant pathogens. Clinical Trials Registration. NCT01445665 and NCT01445678. Oxford University Press 2015-05-15 2015-02-10 /pmc/articles/PMC4412191/ /pubmed/25670823 http://dx.doi.org/10.1093/cid/civ097 Text en © The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.
spellingShingle Articles and Commentaries
Solomkin, Joseph
Hershberger, Ellie
Miller, Benjamin
Popejoy, Myra
Friedland, Ian
Steenbergen, Judith
Yoon, Minjung
Collins, Sylva
Yuan, Guojun
Barie, Philip S.
Eckmann, Christian
Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)
title Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)
title_full Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)
title_fullStr Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)
title_full_unstemmed Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)
title_short Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)
title_sort ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (aspect-ciai)
topic Articles and Commentaries
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412191/
https://www.ncbi.nlm.nih.gov/pubmed/25670823
http://dx.doi.org/10.1093/cid/civ097
work_keys_str_mv AT solomkinjoseph ceftolozanetazobactamplusmetronidazoleforcomplicatedintraabdominalinfectionsinaneraofmultidrugresistanceresultsfromarandomizeddoubleblindphase3trialaspectciai
AT hershbergerellie ceftolozanetazobactamplusmetronidazoleforcomplicatedintraabdominalinfectionsinaneraofmultidrugresistanceresultsfromarandomizeddoubleblindphase3trialaspectciai
AT millerbenjamin ceftolozanetazobactamplusmetronidazoleforcomplicatedintraabdominalinfectionsinaneraofmultidrugresistanceresultsfromarandomizeddoubleblindphase3trialaspectciai
AT popejoymyra ceftolozanetazobactamplusmetronidazoleforcomplicatedintraabdominalinfectionsinaneraofmultidrugresistanceresultsfromarandomizeddoubleblindphase3trialaspectciai
AT friedlandian ceftolozanetazobactamplusmetronidazoleforcomplicatedintraabdominalinfectionsinaneraofmultidrugresistanceresultsfromarandomizeddoubleblindphase3trialaspectciai
AT steenbergenjudith ceftolozanetazobactamplusmetronidazoleforcomplicatedintraabdominalinfectionsinaneraofmultidrugresistanceresultsfromarandomizeddoubleblindphase3trialaspectciai
AT yoonminjung ceftolozanetazobactamplusmetronidazoleforcomplicatedintraabdominalinfectionsinaneraofmultidrugresistanceresultsfromarandomizeddoubleblindphase3trialaspectciai
AT collinssylva ceftolozanetazobactamplusmetronidazoleforcomplicatedintraabdominalinfectionsinaneraofmultidrugresistanceresultsfromarandomizeddoubleblindphase3trialaspectciai
AT yuanguojun ceftolozanetazobactamplusmetronidazoleforcomplicatedintraabdominalinfectionsinaneraofmultidrugresistanceresultsfromarandomizeddoubleblindphase3trialaspectciai
AT bariephilips ceftolozanetazobactamplusmetronidazoleforcomplicatedintraabdominalinfectionsinaneraofmultidrugresistanceresultsfromarandomizeddoubleblindphase3trialaspectciai
AT eckmannchristian ceftolozanetazobactamplusmetronidazoleforcomplicatedintraabdominalinfectionsinaneraofmultidrugresistanceresultsfromarandomizeddoubleblindphase3trialaspectciai